What Is the Optimal Approach to Major ABO-Incompatible Allogeneic Stem Cell Transplantation?

This is the authors' abstract. We don't add key points for this paper.

In a recent issue of BBMT, Booth et al. [1] reviewed approaches to the management of ABO-incompatible allogeneic hematopoietic progenitor cell (HPC) transplantation (HCT). Major ABO incompatibility may be addressed by RBC depletion of the HPC product or reduction of recipient isohemagglutinins by plasma exchange, column immunoadsorption, donor-type secretor plasma, or in vivo immunoadsorption using donor RBCs [2-6]. As the authors state in their review, there is no consensus as to the best method of managing ABO-incompatible HCT [2], and there have been no direct comparisons of available methods.